Norman E Sharpless
Overview
Explore the profile of Norman E Sharpless including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
19277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bachoo R, Maher E, Ligon K, Sharpless N, Chan S, You M, et al.
Cancer Cell
. 2024 Dec;
42(12):2124.
PMID: 39663072
No abstract available.
2.
Abdou Y, Sharpless N
J Clin Oncol
. 2024 Sep;
42(33):3887-3890.
PMID: 39331856
No abstract available.
3.
Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, et al.
Cancer Discov
. 2024 Jul;
14(7):1356.
PMID: 38946327
No abstract available.
4.
Souroullas G, Jeck W, Parker J, Simon J, Liu J, Paulk J, et al.
Nat Med
. 2024 Feb;
30(6):1784.
PMID: 38383796
No abstract available.
5.
Flores-Toro J, Jagu S, Armstrong G, Arons D, Aune G, Chanock S, et al.
J Clin Oncol
. 2023 Jun;
41(24):4045-4053.
PMID: 37267580
Data-driven basic, translational, and clinical research has resulted in improved outcomes for children, adolescents, and young adults (AYAs) with pediatric cancers. However, challenges in sharing data between institutions, particularly in...
6.
Choi Y, Erlich T, von Franque M, Rachmin I, Flesher J, Schiferle E, et al.
Cell
. 2022 May;
185(12):2071-2085.e12.
PMID: 35561684
Giant congenital melanocytic nevi are NRAS-driven proliferations that may cover up to 80% of the body surface. Their most dangerous consequence is progression to melanoma. This risk often triggers preemptive...
7.
Pinto L, Shawar R, OLeary B, Kemp T, Cherry J, Thornburg N, et al.
Microbiol Spectr
. 2022 Jan;
10(1):e0156421.
PMID: 35019677
The emergence of SARS-CoV-2 created a crucial need for serology assays to detect anti-SARS-CoV-2 antibodies, which led to many serology assays entering the market. A trans-government collaboration was created in...
8.
Kerlavage A, Kirchhoff A, Guidry Auvil J, Sharpless N, Davis K, Reilly K, et al.
JCO Clin Cancer Inform
. 2021 Aug;
5:881-896.
PMID: 34428097
Cancer Informatics for Cancer Centers (CI4CC) is a grassroots, nonprofit 501c3 organization intended to provide a focused national forum for engagement of senior cancer informatics leaders, primarily aimed at academic...
9.
10.
Althoff K, Schlueter D, Anton-Culver H, Cherry J, Denny J, Thomsen I, et al.
Clin Infect Dis
. 2021 Jun;
74(4):584-590.
PMID: 34128970
Background: With limited severe acute respiratory syndrome coronavirus (SARS-CoV-2) testing capacity in the United States at the start of the epidemic (January-March 2020), testing was focused on symptomatic patients with...